Eevia Health receives multiple sales orders for c. Ksek 635 (KEUR 56)

Report this content

Eevia Health PLC ("Eevia" or "The Company") received several sales orders for extracts totaling KEUR 56 from various European and Asian customers.

A total of 56 KEUR of sales orders came in from several customers. One order came from our distributor Breko, for Feno-Myrtillus 25 Organic and Feno-Myrtillus 5 Organic (Bilberry Extracts) and Fenoprolic Full Spectrum Extract (a pine bark extract) for the sum of KEUR 18.  

Another repeat sales order is from a European nutraceutical brand owner headquartered in Sweden. The new order of KEUR 21 is an increase of an order of KEUR 51 that Eevia received in June. The volume will be delivered this week.

Additionally, Eevia has received several smaller orders from Finnish customers for a total of KEUR 9 as well as a repeat order from a regular customer in Taiwan for KEUR 8. The products are Fenoprolic 70 Organic (Pine bark extract), Feno-Myrtillus 25 Organic (Bilberry extract), Feno-Vitis 5 (Lingonberry extract), and Bilberry Berry powder.

All products are in stock and the orders are helpful for operational cash flow.

 

 

 

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com                      

Telephone: +358 400 22 5967                         

 

 

 

 

 

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.